Mark Chataway is an expert in policy analysis and development, opinion research and communications. Although originally a journalist, he started working in public health in the early days of the HIV epidemic in the USA. Since, he has worked on adult and paediatric vaccine issues in Africa, Asia, Latin America, Europe and North America. Mark has been involved in programmes on routine immunisation; introduction of new paediatric vaccines; policy on HIV, HPV, malaria and TB vaccines; uptake of adult immunisation against flu and pneumococcal disease and; vaccines for use in epidemics and against emerging pathogens. He is particularly interested in how governments establish prevention policy priorities and in public understanding of vaccines.
Mark has worked for governments such as the European Commission, India and South Africa; for intergovernmental organisations such as the International AIDS Vaccine Initiative, the IBSA alliance, Gavi and the WHO; for academic institutions including Johns Hopkins Bloomberg School of Public Health, the London School of Hygiene and Tropical Medicine and RAND; for non-governmental groups such as the Bill & Melinda Gates Foundation and PATH and; for all of the world’s major vaccine research and production companies. Mark is the Director of Hyderus Cyf, a consultancy based in Wales and co-chairman of Baird’s CMC, a global consultancy group owned by 40 shareholders in over 30 countries. Mark speaks good French and Portuguese and native proficiency English and Welsh.